Skip to main content

News Room

  • December 1-2 – LumaCyte CEO and CSO to speak opening morning at 10am, PAT & Real Time Quality Summit: A Quality by Design Approach with Laser Force Cytology Real-time Predictive Analytics. LumaCyte is proud to be the lead sponsor at the inaugural PAT & Real Time Quality Summit being held in San Diego. Please join Renee Hart, LumaCyte’s President and Chief Business Officer, as she discusses along with industry colleagues the importance of actionable analytics

  • September 27-30 – LumaCyte to exhibit as a bronze sponsor at the annual Bioprocess International conference in Boston, MA

  • July 26-28 – Sean Hart, PhD, Renee A. Hart, and Colin Hebert from the LumaCyte team were invited to talk and to share a poster at the NIIMBL 2022 National Meeting.

  • July 15 – GEN sponsored webinar featuring Dr. Peter Marks, MD, PhD, who will be discussing the growing need for improved production and product consistency through better analytical data. The biopharma industry is evolving at an accelerated rate driving with it the need for faster, more precise analytics. Biomanufacturing veteran, James Robinson, will also share industry case studies illustrating how accurate analytics provided in real-time can significantly improve production outcomes and quality.

  • June 12-17 – LumaCyte’s Poster Accurate and Precise Viral Quantification for Rapid Vaccine Development and In-Process Production Monitoring using Radiance® Laser Force Cytology™ was at the ECI Vaccine Technology VIII Conference in Sitges, Spain.

  • May 3 – Read the latest newsletter from GEN Genetic Engineering & Biotechnology News. LumaCyte Advances in BioProcessing: Digitization, Vaccine Developments, and the FDA Seeks Consistency.

  • March 1 – Jim Robinson, Scientific Advisory Board, LumaCyte and former Chair of CEPI Scientific Advisory Committee and Colin Hebert, VP Biotechnology, LumaCyte to host round table discussion with industry production scientists, Real-time Bioprocess Analytics Delivering Improved Production Consistency and Increased Product Yields at the 2022 World Vaccine Congress in Washington, DC April 19 at 11:30 and 12:45.

  • February 15 – LumaCyte announced the appointment of two industry executives, Paul M. Meister, Past Chairman of the Board, Thermo Fisher Scientific and Peter Buzy, Former Chairman of Catalent’s Gene Therapy Division to the Board of Directors.

  • January 10 – LumaCyte is a proud Gold Sponsor of the 2022 World Vaccine Congress being held in Washington, DC April 18-21. Please come out and meet our team!

  • January 11 – LumaCyte Laser Force Cytology (LFC) was recently published in Springer Method, Vaccine Delivery Technology book where a full chapter is dedicated to Radiance and LFC rapid viral infectivity quantification assay.

  • January 26 – Lumacyte CSO, Sean Hart, PhD and Catalent Pharma Solutions Director of Internal R&D & Product Development, Bhargavi Kondragunta, Ph.D. were featured speakers at the Fierce Biotech Webinar: Are Real-Time Gene Therapy Test Results Possible?

  • April 20 –  Jim Robinson joins the LumaCyte Scientific Advisory Board (SAB). Jim brings more than 35 years of CMC vaccine manufacturing experience to the LumaCyte SAB, holding previous executive level positions at Merck, Sanofi Pasteur and Novavax, and is currently a member and the Vice Chair of the Coalition for Epidemic Preparedness Innovations (CEPI) Scientific Advisory Committee. Read the full press release.

  • September 29 – Cells were infected two hours post seeding and then harvested for analysis with Radiance at 48 hours post infection in two separate experiments in order to demonstrate LFC’s ability to quantify adenovirus infection in HEK 293 cells. Read the Technical Note: Radiance® Label-Free Monitoring of Adenovirus Infection of HEK293 Cells.

  • October 6 – NIIMBL | The National Institute for Innovation in Manufacturing Biopharmaceuticals invited Renee Hart, LumaCyte’s President & CBO, to present to NIIMBL’s pharma, CDMO, and government members on the value of Laser Force Cytology in accelerating vaccine development and production.
  • September 30 – LumaCyte is awarded Highly Commended for the Best Production/Process Development Award at the World Vaccine Congress Vaccine Industry Excellence (VIE) Awards.
  • September 28 – October 1 – LumaCyte is a Gold Sponsor, Speaker, and Exhibitor at the World Vaccine Congress Virtual Event.
  • September 14 – LumaCyte’s CEO & CSO Sean Hart, PhD discusses how to “Overcome Vaccine Production Bottlenecks with Real-time Infectivity – When Saving Time Means Saving Lives” at the World Vaccine Congress.
  • June 2 – Catalent and LumaCyte collaborated efforts to compare AAV production with three different transfection reagents using both LFC and a digital droplet PCR (ddPCR) based viral genome titer assay in the Technical Note: Radiance® Label-Free Monitoring of AAV Transfection in HEK293 Cells Using Laser Force Cytology™. Read the press release here.
  • March 30 –  LumaCyte Laser Force Cytology demonstrates detection of human coronavirus (OC43) infectivity using its Radiance instrument. Rapid detection of infectivity is critical for proper assessment of vaccine candidates, manufacturing, inactivation, and formulations testing. See the Tech Note
  • March 20 – LumaCyte achieves Underwriters Laboratories U/L certification for electrical and safety for Radiance +Autosampler products.
  • February 1 – LumaCyte welcomes Dr. Christof Hasse as Executive Director Business Development, – Europe. Christof comes to LumaCyte with 25 years’ experience in biopharma analytical instrumentation.
  • January 28 – LumaCyte launches European subsidiary, LumaCyte, B.V., in the Netherlands to serve as its hub for instrument sales and service in EMEA. Having resources close to our customers is critical for maintaining outstanding customer service and support. Read the press release
  • September 12 – LumaCyte primed for significant global growth: CE mark opens European market. LumaCyte an advanced research and bioanalytics instrumentation company headquartered in Charlottesville, VA, announces third doubling of their manufacturing and laboratory space.

  • June 1 – LumaCyte will be a Platinum sponsor and exhibitor at the European Society of Cell & Gene Therapy (ESGCT) congress in Barcelona on October 22-25, 2019.

  • May 1 – LumaCyte to sponsor and exhibit at the World Vaccine Congress Europe in Barcelona, October 28-31, 2019

  • April 22 – LumaCyte sponsors ECI Vaccines VIII in Barcelona, Spain, in June, 2020.

  • April 15 – LumaCyte to exhibit at the Generis American Biomanufacturing Summit in San Francisco on June 18-19, 2019.

  • April 16 – LumaCyte was awarded the Best Production/Process Development 2019 Vaccine Industry Excellence Award.

  • April 14-17 – LumaCyte’s CEO, Sean Hart, PhD, and Gray Heppner, MD, FACP, FASTMH, from LumaCyte’s Scientific Advisory Board, lead the Interactive Round Table discussion on Replacing antiquated assays with rapid viral vaccine infectivity measurements and process analytical technologies (PAT) at World Vaccine Congress in Washington DC.

  • April 8 – LumaCyte executives participated in the 2019 BioHealth Capital Region Forum as they discussed New Tools in Therapeutics with GSK, Arcellx, MaxCyte, Inc. and Serpin Pharma.

  • April – Radiance +Autosampler achieves European Economic Area (EEA) health, safety and environmental protection standards to support growing global demand.

  • March 14 – LumaCyte to participate in the Virginia Bio Commercialization Luncheon, “Dynamic Duo Lights the Way to Cell Discovery” on Thursday, March 14, 2019 at the Virginia Bio+Tech Park.

  • March 7 – LumaCyte was selected as a finalist for this year’s Vaccine Industry Excellence (ViE) Awards on April 15, held in conjunction with the 19th World Vaccine Congress, April 14-17 in Washington D.C. for the category of “Best Production/Process Development Award”.

  • March 6 – Dr. Delphine Le Roux’s technology poster was voted ‘top 5 best posters’ by the meeting attendees at ISBiotech’s 9th Spring Meeting in Norfolk, VA.

  • March 4 – Dr. Colin Hebert presented a technology workshop at ISBiotech’s 9th Spring Meeting in Norfolk, VA: From Vaccines to Cell Therapy Biomanufacturing: Applications of Laser Force Cytology for Rapid Viral Infectivity Measurements and Label-Free Biomarker Development.

  • March 4-6 – LumaCyte attends ISBiotech’s 9th Spring Meeting in Norfolk, VA.

  • February 21 – LumaCyte to host a roundtable discussion at the World Vaccine Congress in Washington, DC on April 18, 2019. The roundtable, Replacing antiquated assays with rapid viral vaccine infectivity measurements and process analytical technologies (PAT), will be moderated by Drs. Gray Heppner and Sean Hart.

  • February 15 – LumaCyte to Gold Sponsor the World Vaccine Congress in Washington DC, Walter E Convention Center, April 6-9, 2020. This will be our fifth year at the event and we look forward to seeing you there!

  • February 5 – LumaCyte to exhibit and attend Generis American Biomanufacturing Summit in San Francisco, June, 2019.

  • January 25 – LumaCyte to exhibit at World Vaccine Congress Europe in Palau de Congressos de Catalunya, Barcelona, Spain, October 29-31, 2019.
  • January 20 – LumaCyte nominated for this year’s Vaccine Industry Excellence (ViE) Award for the category of “Best Production/Process Development Award”.
  • January 9 – LumaCyte wins National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) grant for workforce development entitled, “Characterization of Cell Therapy Products by Flow and Laser Force Cytometry” with Rensselaer Polytechnic Institute and Celgene.
  • January 7-9 – LumaCyte executives attend JP Morgan Healthcare Week Conferences in San Francisco.

    • December 12 – LumaCyte’s Radiance instrument was used to support new immunotherapy research for melanoma. Read the new oncolytic virus immunotherapy paper in Science Translational Medicine to learn more.

    • December 12 – LumaCyte was invited to give a talk at the MIT Center for Biomedical Innovation’s 2018 BioMAN Summit in Boston. Our Vice President, Dr. Colin Hebert gave a presentation on Cellular Biophysical Characterization for Cell and Gene Therapy.

    • November 14 – LumaCyte CEO/CSO was a co-author on National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) vaccines biomanufacturing roadmap produced by BioPhorum Operations Group (BPOG). Dr. Hart led the Analytical, Modeling, and Knowledge Management sections writing about the use of new analytical technologies and methods for advanced vaccine biomanufacturing.

    • October – Dr. Colin Hebert participated in the NIIMBL adventitious agent testing (AAT) meeting at Merck.

    • September 12 – LumaCyte publishes peer-reviewed article in the journal Vaccine detailing the use of their Radiance instrument for rapid viral infectivity measurements with vesicular stomatitus virus (VSV) as a replacement for TCID50.

    • September 4 – LumaCyte, one of the recipients of NIIMBL | The National Institute for Innovation in Manufacturing Biopharmaceuticals’s Quick Start Project (QSP) Award, is collaborating with Genetech & Carnegie Mellon University on a project focused on Adventitous Agent Testing.

    • August 30 – LumaCyte announces the award of a project through National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) for adventitious agent testing (AAT) with Genentech and Carnegie Mellon University.

    • August 7 – Renee Hart, LumaCyte’s President & Chief Business Officer was invited to present on the Healthcare Businesswomen’s Association (HBA) Career Conversations Webinar. With record webinar attendance levels, Renee shared insights and experience that could benefit other women as they strive to accelerate their careers.

    • June 21 – LumaCyte’s CEO Sean Hart presenting on Laser Force Cytology and applications in vaccine development and production at ECI Conference, Vaccine Technology VII in Mont Tremblant, Quebec, Canada.

    • May 15 – Dr. Sean J. Hart, LumaCyte CEO invited to present at Ideagen’s Annual Global Leadership 2030 Summit [3] on the Power Panel: Disruption 2030, focused on healthcare innovation at Gallup’s Headquarters in Washington, DC June 7th, 2018.

    • May 4 – LumaCyte to exhibit at the World Vaccine Congress in Washington DC, April 14-17, 2019. This will be our fourth year at this event and we look forward to seeing you there!

    • May 1 – LumaCyte invited to join the Advanced Virus Detection Technologies Interest Group (AVDTIG). This group is dedicated to finding new and advanced methods for the rapid detection of adventitious viruses to ensure biologic drug safety. [5]

    • April 15 – LumaCyte to sponsor and present at the ECI Conference, Vaccine Technology VII [6] on June 17-22, 2018 in Mont Tremblant, Quebec, Canada.

    • April 10 – LumaCyte to attend the NIIMBL National Meeting [7] in Washington DC April 15-16 at the National Academy of Sciences [8].

    • April 3 – LumaCyte exhibited and attended the World Vaccine Congress in Washington DC. Thank you to our customers, both new and existing, for visiting with us and discussing applications of our products & technology.

    • April 1 – LumaCyte wins grant from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) [10] for Adventitious Agent Detection (AAT).
    • February 15 – LumaCyte launches their Single Cyte Blog – dedicated to all things single cell analysis. Check back often for article reviews, news, technology highlights, and more.
    • February 1 – LumaCyte welcomes Ms. Carolyn Maki as our Vice President of Business Development & Partnerships. Carolyn joins us from PPD where she was Executive Director, BD for Central Labs.
    • January 12 – LumaCyte’s VP of biotechnology, Dr. Colin Hebert, presented a workshop entitled “Laser Force Cytology: A Novel Technology for Rapid Quantification of Viral Infectivity and Label-Free Cellular Analysis” at International Society for Bioprocess Technology, ISBioTech’s spring meeting on March 5th, 2018 in Norfolk, VA.
    • January 4 – LumaCyte to present at the 2018 World Vaccine Congress in Washington DC April 3-5, 2018.

 

  • December 19 – LumaCyte featured in National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) monthly newsletter.

  • December 1 – LumaCyte welcomes Dr. Margaret McCoy, PhD, JD as Executive Director Assay Development & Regulatory Affairs. Link
    Dr. McCoy will lead clinical application and product development and also coordinate regulatory matters.

  • November 15 – LumaCyte welcomes Keya Rodrigues, MS as a bioengineer. Link
    Ms. Rodrigues will work on applications development using Laser Force Cytology and new product R&D.

  • October 3 – LumaCyte’s Drs. Colin Hebert and Sean Hart co-publish paper with scientists at the Naval Research Laboratory (NRL) on macrophage phagocytosis detection and monitoring using laser optical forces. See the paper here

  • September 7 – LumaCyte joins The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a Manufacturing USA institute sponsored by the National Institute of Standards and Technology (NIST). Link to Press Release

  • September 1 – LumaCyte welcomes Thang Nguyen, MS, as a senior software engineer. Mr. Nguyen is a certified LabVIEW Architect and LabVIEW instructor and will work on development of software for LumaCyte’s products and applications.

  • May 15 – LumaCyte announces that is a founding sponsor of the CvilleBioHub. The CvilleBioHub is an organization that was created to connect and help grow the biotech and life sciences communities, while bringing awareness of the Charlottesville area as a biotech center in central Virginia.

  • April 11 – LumaCyte unveils and demonstrates its much anticipated 96 well plate autosampler at the World Vaccine Congress.

  • April 10 – LumaCyte & Thermo Fisher Scientific presented a poster entitled, “Rapid Quantification of Vesicular Stomatitis Virus Infectivity in Vero Cells using Laser Force Cytology”, at the World Vaccine Congress.

  • April 10 – LumaCyte & Rutgers Cancer Institute of New Jersey (CINJ) presented a poster entitled, “Monitoring the Oncolytic Effect of Talimogene laherparepvec (T-VEC) in combination with the MEK inhibitor Trametinib using Laer Force Cytology”, presented at the World Vaccine Congress.

  • April 10-12 – LumaCyte exhibits at the World Vaccine Congress in Washington, DC.

  • March 6-8 – LumaCyte and Nanotherapeutics, Inc. presented a poster entitled, “Rapid Quantification of Viral Infectivity in a Recombinant Baculovirus System using Laser Force Cytology” at the ISBiotech Spring 2017 meeting in Washington, DC.

  • December 28 – LumaCyte signs Material Transfer Agreement (MTA) with the United States Army Medical Research Institute for Infectious Diseases (USAMRIID). LumaCyte is collaborating with USAMRIID using Radiance instrument for the analysis of Zika virus infected mammalian cells for rapid infectivity and neutralization assays.

  • December 16 – LumaCyte was excited and honored to be present for the announcement of the nearly $200 million National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) at the University of Delaware.

  • December 12 – LumaCyte’s role in Zika R&D featured in newspaper article.

  • December 1 – LumaCyte featured in NBC29 nightly news segment on Zika virus research.

  • November 15 – LumaCyte to present at CVille Biohub’s Zika Virus Forum in Charlottesville, VA, December 1, 2016.

  • August 8 – LumaCyte will exhibit at the World Vaccine Congress in Washington DC, April 10-12, 2017.

  • August 2 – LumaCyte invited to present keynote address in the Vision Summit Meeting at National Instruments’ conference in Austin, TX on August 2-4, 2016

  • March 3 – Join LumaCyte at their exhibit booth #13 at the World Vaccine Congress 2016 in Washington DC, March 29-31, 2016.

  • February 26 – LumaCyte is please to announce it’s inclusion and participation in the Zika Response Working Group.

  • September 23 – LumaCyte to sponsor and exhibit at the World Vaccine Congress 2016 in Washington DC, March 29-31, 2016.

  • September 15 – LumaCyte to sponsor and present at the Vaccine R&D 2015 Conference, November 2-4, 2015 in Baltimore, MD.

  • August 2 – Article published in Cytofluidix, an online microfluidics technology review.

  • March 16 – Dr. Sean J. Hart to present the keynote lecture at Suffolk University’s annual STEM Reception on April 27, 2015.

  • February 23 – Dr. Sean J. Hart to present at Mid-Atlantic Directors & Staff of Scientific Cores Meeting on June 3 rd -4 th http://madssci.abrf.org/
  • February 1 – LumaCyte welcomes Dr. Colin Hebert to the team as Vice President, Biotechnology. Dr. Hebert comes to LumaCyte from the Bio/Analytical Chemistry Section at the Naval Research Laboratory (NRL) where he collaborated with LumaCyte to develop their novel label-free cell analysis and sorting technology.
  • January 1 – LumaCyte has moved into its new biosafety level two (BSL-2) laboratory and office in Charlottesville!
  • May 10 – LumaCyte has delivered its first prototype cell analysis and sorting instrument to the flow cytometry core facility at the University of Virginia (UVA) School of Medicine for testing.
  • March 5 – LumaCyte has entered into a Collaborative Research and Development Agreement (CRADA) with the Naval Research Laboratory (NRL), Washington, DC for the development of optical instrumentation for cell analysis and sorting.
  • January 18 – LumaCyte establishes collaboration with medical researchers at the University of Virginia (UVA) School of Medicine.
  • January 6 – Dr. Sean J. Hart will be presenting an invited talk at NanoTech in June 2014. His presentation will be focused around disease detection and characterization in mammalian cells using our novel cell analysis and sorting system currently under development. Link
Close Menu